Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press30010.17650/1726-9776-2010-6-3-48-50PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPREDICTION OF COMPLICATIONS DUE TO INTRATISSUE RADIOTHERAPY IN MULTIMODALITY TREATMENT FOR PROSTATE CANCERПРОГНОЗИРОВАНИЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ ПОСЛЕ ПРОВЕДЕНИЯ ВНУТРИТКАНЕВОЙ ЛУЧЕВОЙ ТЕРАПИИ ПРИ КОМПЛЕКСНОМ ЛЕЧЕНИИ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫKostinА. А.КостинА. А.
Russian Federation
kaprin@mail.ruSeminA. V.СеминА. В.
Russian Federation
kaprin@mail.ruKaprinA. D.КапринА. Д.
Russian Federation
kaprin@mail.ruTsybulskyA. D.ЦыбульскийА. Д.
Russian Federation
kaprin@mail.ruRussian X-ray Radiology Research Center, Russian Agency for Medical Technologies, MoscowФГУ РНЦРР, Москва300920106348500508201405082014https://oncourology.abvpress.ru/oncur/article/view/300

The study of postbrachytherapy complications identified a number of factors that significantly influenced the development of lower urinary tract (LUT) complications. These factors may include prostate volume and preoperative degree of LUT symptoms. The combined effect of these factors increases a risk for the complications.

При исследовании осложнений, возникающих у больных после проведения брахитерапии, был выделен ряд факторов, достоверно влияющих на развитие осложнений со стороны нижних мочевых путей. К таким факторам можно отнести объем предстательной железы, низкую пиковую скорость мочеиспускания, предоперационное число симптомов со стороны нижних мочевых путей. Совместное действие этих факторов повышает риск развития осложнений.

brachytherapyprostateintratissue radiotherapyбрахитерапияпредстательная железавнутритканевая лучевая терапия1. Hudson R. Brachytherapy treatments increasing among Medicare population. Health Policy Brief of the American Urologic Association, Inc, 1999:9:1.Hudson R. Brachytherapy treatments increasing among Medicare population. Health Policy Brief of the American Urologic Association, Inc, 1999:9:1.2. Ash D., Flynn A., Battermann J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21.Ash D., Flynn A., Battermann J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21.3. Blasko J.C., Grimm P.D., Sylvester J.E. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839−50.Blasko J.C., Grimm P.D., Sylvester J.E. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839−50.4. Grimm P.D., Blasko J.C., Sylsvester J.E. 10-year biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 2001;51:31−40.Grimm P.D., Blasko J.C., Sylsvester J.E. 10-year biochemical (PSA) control of prostate cancer with Iodine-125 brachytherapy. Int J Radiat Biol Phys 2001;51:31−40.5. Ragde H., Korb L., Elgamal A. 12-year follow-up after transperineal brachytherapy of localized prostate cancer. J Urol Suppl 2000;163:336−7.Ragde H., Korb L., Elgamal A. 12-year follow-up after transperineal brachytherapy of localized prostate cancer. J Urol Suppl 2000;163:336−7.6. Ash D., Bottomley D., Al-Qaisieh B. et al. A prospective analysis of long-term quality of life after permanent I-125 brachythrapy for localised prostate cancer. Radiother Oncol 2007;84:135–9.Ash D., Bottomley D., Al-Qaisieh B. et al. A prospective analysis of long-term quality of life after permanent I-125 brachythrapy for localised prostate cancer. Radiother Oncol 2007;84:135–9.7. Bottomley D., Ash D., Al-Qaisieh B. et al. Side effects of permanent I-125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 2007;82:46–9.Bottomley D., Ash D., Al-Qaisieh B. et al. Side effects of permanent I-125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 2007;82:46–9.8. Brandeis J.M., Litwin M.S., Burnison C.M., Reiter R.E. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163:851–7.Brandeis J.M., Litwin M.S., Burnison C.M., Reiter R.E. Quality of life outcomes after brachytherapy for early stage prostate cancer. J Urol 2000;163:851–7.9. Caffo O., Fellin G., Bolner A. et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:31–7.Caffo O., Fellin G., Bolner A. et al. Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2006;66:31–7.